JP2009542696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009542696A5 JP2009542696A5 JP2009518393A JP2009518393A JP2009542696A5 JP 2009542696 A5 JP2009542696 A5 JP 2009542696A5 JP 2009518393 A JP2009518393 A JP 2009518393A JP 2009518393 A JP2009518393 A JP 2009518393A JP 2009542696 A5 JP2009542696 A5 JP 2009542696A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- group
- substituted
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 **N1CCOCC1 Chemical compound **N1CCOCC1 0.000 description 4
- GKOAQPMFDRAARM-ULKWEWGCSA-N CC(C)C1(C)SC=C(CN(C)C(N[C@@H](C(C)COC)C(O)=O)=O)N1 Chemical compound CC(C)C1(C)SC=C(CN(C)C(N[C@@H](C(C)COC)C(O)=O)=O)N1 GKOAQPMFDRAARM-ULKWEWGCSA-N 0.000 description 1
- AYNKEDQCQUBXKC-PXTZSQHASA-N CC(C)[C@@H](C(N(C)[C@H](CC[C@H](Cc1ccccc1)NC(OCc1cnc[s]1)=O)Cc1ccccc1)=O)NC(N(C)Cc1c[s]c(C(C)C)n1)=O Chemical compound CC(C)[C@@H](C(N(C)[C@H](CC[C@H](Cc1ccccc1)NC(OCc1cnc[s]1)=O)Cc1ccccc1)=O)NC(N(C)Cc1c[s]c(C(C)C)n1)=O AYNKEDQCQUBXKC-PXTZSQHASA-N 0.000 description 1
- FYFOKJMLOCALAN-QSCLJHCWSA-N CC(C)[C@@H](C(N[C@H](CC[C@H](Cc1ccccc1)NC(/[O]=C/c1cnc[s]1)=O)Cc1ccccc1)=O)NC(N(C)Cc1c[s]c(C(C)C)n1)=O Chemical compound CC(C)[C@@H](C(N[C@H](CC[C@H](Cc1ccccc1)NC(/[O]=C/c1cnc[s]1)=O)Cc1ccccc1)=O)NC(N(C)Cc1c[s]c(C(C)C)n1)=O FYFOKJMLOCALAN-QSCLJHCWSA-N 0.000 description 1
- MERJVZJITHOBLN-ZIHXJKBXSA-N CC(C)c1nc(CN(C)C(N[C@@H](C(C)OC)C(NCCC[C@H](Cc2ccccc2)NC(OCc2cnc[s]2)=O)=O)=O)c[s]1 Chemical compound CC(C)c1nc(CN(C)C(N[C@@H](C(C)OC)C(NCCC[C@H](Cc2ccccc2)NC(OCc2cnc[s]2)=O)=O)=O)c[s]1 MERJVZJITHOBLN-ZIHXJKBXSA-N 0.000 description 1
- WJGZIEIFZQIJPA-KFJBMODSSA-N CC(C)c1nc(CN(C)C(N[C@@H](C(C)OC)C(OC)=O)=O)c[s]1 Chemical compound CC(C)c1nc(CN(C)C(N[C@@H](C(C)OC)C(OC)=O)=O)c[s]1 WJGZIEIFZQIJPA-KFJBMODSSA-N 0.000 description 1
- LQRJNXNJJBAJRE-PUCLRWMGSA-N CC(C)c1nc(CN(C)C(N[C@@H](C/C(/O)=[O]/C)C(N[C@H](CC[C@H](Cc2ccccc2)NC(OCc2cnc[s]2)=O)Cc2ccccc2)=O)=O)c[s]1 Chemical compound CC(C)c1nc(CN(C)C(N[C@@H](C/C(/O)=[O]/C)C(N[C@H](CC[C@H](Cc2ccccc2)NC(OCc2cnc[s]2)=O)Cc2ccccc2)=O)=O)c[s]1 LQRJNXNJJBAJRE-PUCLRWMGSA-N 0.000 description 1
- UGINBIFFWPEJLE-GLGOKHISSA-N CC(C)c1nc(CN(C)C(N[C@H](C(C)OC(C)(C)C)C(O)=O)=O)c[s]1 Chemical compound CC(C)c1nc(CN(C)C(N[C@H](C(C)OC(C)(C)C)C(O)=O)=O)c[s]1 UGINBIFFWPEJLE-GLGOKHISSA-N 0.000 description 1
- FYCWLJLGIAUCCL-BKLSDQPFSA-N CC([C@@H](C(O)=O)N)OC Chemical compound CC([C@@H](C(O)=O)N)OC FYCWLJLGIAUCCL-BKLSDQPFSA-N 0.000 description 1
- ZGSFKAVIRXLMRI-AKGZTFGVSA-N CC([C@@H](C(OC)=O)N)OC Chemical compound CC([C@@H](C(OC)=O)N)OC ZGSFKAVIRXLMRI-AKGZTFGVSA-N 0.000 description 1
- IFKONDWPXROQGA-UHFFFAOYSA-N OC([n]1cncc1)=S Chemical compound OC([n]1cncc1)=S IFKONDWPXROQGA-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81931506P | 2006-07-07 | 2006-07-07 | |
| US60/819,315 | 2006-07-07 | ||
| US83237106P | 2006-07-21 | 2006-07-21 | |
| US60/832,371 | 2006-07-21 | ||
| US90322807P | 2007-02-23 | 2007-02-23 | |
| US60/903,228 | 2007-02-23 | ||
| PCT/US2007/015604 WO2008010921A2 (en) | 2006-07-07 | 2007-07-06 | Modulators of pharmacokinetic properties of therapeutics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011239688A Division JP2012051933A (ja) | 2006-07-07 | 2011-10-31 | 治療薬の薬物動態の調整 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009542696A JP2009542696A (ja) | 2009-12-03 |
| JP2009542696A5 true JP2009542696A5 (https=) | 2011-02-17 |
| JP4881433B2 JP4881433B2 (ja) | 2012-02-22 |
Family
ID=38729072
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009518393A Active JP4881433B2 (ja) | 2006-07-07 | 2007-07-06 | 治療薬の薬物動態の調整 |
| JP2011239688A Withdrawn JP2012051933A (ja) | 2006-07-07 | 2011-10-31 | 治療薬の薬物動態の調整 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011239688A Withdrawn JP2012051933A (ja) | 2006-07-07 | 2011-10-31 | 治療薬の薬物動態の調整 |
Country Status (33)
| Country | Link |
|---|---|
| US (11) | US8067449B2 (https=) |
| EP (5) | EP2049506B2 (https=) |
| JP (2) | JP4881433B2 (https=) |
| KR (3) | KR20140004808A (https=) |
| CN (2) | CN103275033B (https=) |
| AP (1) | AP2985A (https=) |
| AR (1) | AR061838A1 (https=) |
| AU (1) | AU2007275860C1 (https=) |
| BR (1) | BRPI0714055B8 (https=) |
| CA (1) | CA2653374A1 (https=) |
| CY (2) | CY1116688T1 (https=) |
| DK (1) | DK2049506T4 (https=) |
| EA (2) | EA020489B1 (https=) |
| ES (4) | ES2796275T3 (https=) |
| FI (2) | FIC20150052I1 (https=) |
| FR (1) | FR15C0078I2 (https=) |
| HR (2) | HRP20150744T4 (https=) |
| HU (1) | HUE025565T4 (https=) |
| IL (2) | IL195488A (https=) |
| LT (1) | LTC2049506I2 (https=) |
| LU (1) | LU92864I2 (https=) |
| ME (1) | ME02258B (https=) |
| MX (1) | MX2009000234A (https=) |
| NL (1) | NL300780I2 (https=) |
| NO (4) | NO343776B1 (https=) |
| NZ (1) | NZ573060A (https=) |
| PL (2) | PL2049506T5 (https=) |
| PT (2) | PT2487165T (https=) |
| RS (1) | RS54237B2 (https=) |
| SG (1) | SG183007A1 (https=) |
| SI (1) | SI2049506T2 (https=) |
| TW (2) | TWI496778B (https=) |
| WO (1) | WO2008010921A2 (https=) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7786153B2 (en) | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
| SG183007A1 (en) | 2006-07-07 | 2012-08-30 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
| WO2008027932A2 (en) * | 2006-08-31 | 2008-03-06 | Abbott Laboratories | Cytochrome p450 oxidase inhibitors and uses thereof |
| RS55195B1 (sr) | 2007-02-23 | 2017-01-31 | Gilead Sciences | Modulatori farmakokinetičkih svojstava terapeutika |
| AU2015204378B2 (en) * | 2007-02-23 | 2017-03-09 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| PL3150586T3 (pl) | 2007-02-23 | 2020-06-01 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości środków terapeutycznych |
| AU2013204817B2 (en) * | 2007-02-23 | 2015-05-07 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| WO2009006199A1 (en) * | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
| AR067184A1 (es) * | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica |
| EP2170851B1 (en) | 2007-07-06 | 2013-09-04 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| WO2009067225A2 (en) * | 2007-11-20 | 2009-05-28 | Concert Pharmaceuticals, Inc. | Boceprevir derivatives for the treatment of hcv infections |
| PT2231628E (pt) | 2008-01-04 | 2015-12-29 | Gilead Sciences Inc | Inibidores de citocromo p450 |
| EP2254582B1 (en) | 2008-01-25 | 2016-01-20 | Chimerix, Inc. | Methods of treating viral infections |
| HRP20151357T1 (hr) | 2008-05-02 | 2016-01-29 | Gilead Sciences, Inc. | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa |
| SG194404A1 (en) | 2008-12-23 | 2013-11-29 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| PT2376088T (pt) | 2008-12-23 | 2017-05-02 | Gilead Pharmasset Llc | Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída |
| KR20110098849A (ko) | 2008-12-23 | 2011-09-01 | 파마셋 인코포레이티드 | 뉴클레오시드 유사체 |
| DK2393485T3 (en) * | 2009-02-06 | 2015-10-26 | Gilead Sciences Inc | Bilayer COVERING ELVITEGRAVIR, COBICISTAT, emtricitabine and tenofovir |
| UA108738C2 (uk) * | 2009-04-03 | 2015-06-10 | Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки | |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| UY33312A (es) | 2010-03-31 | 2011-10-31 | Pharmasset Inc | Fosforamidato de nucleosido de purina |
| PT2609923T (pt) | 2010-03-31 | 2017-08-30 | Gilead Pharmasset Llc | Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo |
| EP2418196A1 (en) * | 2010-07-29 | 2012-02-15 | IMTM GmbH | Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors |
| MY158809A (en) * | 2010-09-22 | 2016-11-15 | Craun Res Sdn Bhd | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
| WO2012045007A1 (en) | 2010-10-01 | 2012-04-05 | Gilead Sciences, Inc. | Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester |
| AU2011336632B2 (en) | 2010-11-30 | 2015-09-03 | Gilead Pharmasset Llc | Compounds |
| US20130280212A1 (en) * | 2010-12-21 | 2013-10-24 | Gilead Sciences, Inc | Inhibitors of cytochrome p450 |
| JP2014513123A (ja) | 2011-05-02 | 2014-05-29 | ギリアード サイエンシーズ， インコーポレイテッド | 無定形固体の塩 |
| LT2729130T (lt) | 2011-07-07 | 2018-01-10 | Janssen Sciences Ireland Uc | Darunaviro derinių kompozicijos |
| HRP20161696T4 (hr) | 2011-08-16 | 2023-10-13 | Gilead Sciences, Inc. | Tenofovir alafenamid hemifumarat |
| PL2709613T5 (pl) | 2011-09-16 | 2020-12-14 | Gilead Pharmasset Llc | Metody leczenia hcv |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| EP4556010A3 (en) | 2011-11-30 | 2025-07-23 | Emory University | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| JP2015503624A (ja) | 2012-01-12 | 2015-02-02 | ギリアード サイエンシーズ， インコーポレイテッド | 医薬組成物およびその調製方法 |
| SG10201509336RA (en) | 2012-02-03 | 2015-12-30 | Gilead Sciences Inc | Methods and intermediates for preparing pharmaceutical agents |
| EP2819644A1 (en) | 2012-03-01 | 2015-01-07 | Gilead Sciences, Inc. | Spray dried formulations |
| CN104540813A (zh) * | 2012-06-27 | 2015-04-22 | 默沙东公司 | 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法 |
| WO2014000178A1 (en) | 2012-06-27 | 2014-01-03 | Merck Sharp & Dohme Corp. | Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
| CN103694196A (zh) * | 2012-09-27 | 2014-04-02 | 上海迪赛诺化学制药有限公司 | 细胞色素p450单加氧酶抑制剂中间体及其制法和用途 |
| JP2016504364A (ja) * | 2012-12-26 | 2016-02-12 | アッシア・ケミカル・インダストリーズ・リミテッド | コビシスタット塩 |
| PT2950786T (pt) | 2013-01-31 | 2020-03-03 | Gilead Pharmasset Llc | Formulação de combinação de dois compostos antivirais |
| WO2014194519A1 (en) | 2013-06-07 | 2014-12-11 | Merck Sharp & Dohme Corp. | Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug |
| CN104370777A (zh) * | 2013-08-13 | 2015-02-25 | 上海迪赛诺化学制药有限公司 | 合成(2r,5r)-1,6-二苯基己烷-2,5-二胺及其盐的中间体及所述中间体的制备方法和应用 |
| EA201690473A1 (ru) | 2013-08-27 | 2017-03-31 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Комбинированный состав двух противовирусных соединений |
| WO2015070367A1 (en) | 2013-11-12 | 2015-05-21 | Merck Sharp & Dohme Corp. | Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
| WO2015070366A1 (en) | 2013-11-12 | 2015-05-21 | Merck Sharp & Dohme Corp. | Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
| US20170035911A1 (en) | 2013-11-29 | 2017-02-09 | Mylan Laboratories Ltd. | Amorphous Cobicistat Solid Dispersion |
| DK3236972T3 (en) | 2014-12-26 | 2021-10-04 | Univ Emory | Antivirale N4-hydroxycytidin-derivativer |
| CN105198829B (zh) * | 2015-08-15 | 2017-10-31 | 浙江永宁药业股份有限公司 | 一种可比司他中间体的制备方法及其中间体和用途 |
| TW201728582A (zh) * | 2016-01-28 | 2017-08-16 | 基利科學股份有限公司 | 結晶型 |
| WO2017160922A1 (en) | 2016-03-16 | 2017-09-21 | Kalyra Pharmaceuticals, Inc. | Analgesic compounds |
| CN105884760B (zh) * | 2016-06-13 | 2019-01-04 | 厦门市蔚嘉化学科技有限公司 | 一种可比司他中间体的制备方法 |
| CN107674039A (zh) * | 2016-08-01 | 2018-02-09 | 上海朴颐化学科技有限公司 | 一种可比西他中间体的制备方法 |
| US20180036289A1 (en) * | 2016-08-04 | 2018-02-08 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
| WO2018064071A1 (en) | 2016-09-27 | 2018-04-05 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
| US11185548B2 (en) | 2016-12-23 | 2021-11-30 | Helmholtz Zentrum Munchen—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Inhibitors of cytochrome P450 family 7 subfamily B member 1 (CYP7B1) for use in treating diseases |
| SI3661937T1 (sl) | 2017-08-01 | 2021-11-30 | Gilead Sciences, Inc. | Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb |
| JP6804790B1 (ja) | 2017-12-07 | 2020-12-23 | エモリー ユニバーシティー | Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 |
| JP7363810B2 (ja) * | 2018-11-26 | 2023-10-18 | 三菱瓦斯化学株式会社 | 水系エポキシ樹脂組成物及びその硬化物 |
| CN111329858B (zh) * | 2018-12-18 | 2022-09-20 | 深圳先进技术研究院 | 一种小分子抑制剂在抑制病毒沉默抑制蛋白中的应用 |
| WO2020197991A1 (en) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| US11718637B2 (en) | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CN116437958A (zh) | 2020-11-11 | 2023-07-14 | 吉利德科学公司 | 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法 |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| JP7765637B2 (ja) | 2021-12-03 | 2025-11-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症のための治療化合物 |
| DK4445900T3 (da) | 2021-12-03 | 2025-08-18 | Gilead Sciences Inc | Terapeutiske forbindelser til hiv-virusinfektion |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TWI867601B (zh) | 2022-07-01 | 2024-12-21 | 美商基利科學股份有限公司 | 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物 |
| KR20250051732A (ko) | 2022-08-26 | 2025-04-17 | 길리애드 사이언시즈, 인코포레이티드 | 광범위 중화 항체를 위한 투여 및 일정 요법 |
| EP4598934A1 (en) | 2022-10-04 | 2025-08-13 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| US20240390349A1 (en) | 2023-04-19 | 2024-11-28 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
| KR20260018877A (ko) | 2023-05-31 | 2026-02-09 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 치료에 유용한 화합물의 고체 형태 |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| KR20260046169A (ko) | 2023-07-28 | 2026-04-06 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료 및 예방을 위한 레나카파비르 주간 투여 레지먼 |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| WO2025080863A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025080850A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TW202515549A (zh) | 2023-10-11 | 2025-04-16 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| US20250230163A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250296932A1 (en) | 2024-03-01 | 2025-09-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2025184609A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025184452A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20260007683A1 (en) | 2024-06-14 | 2026-01-08 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2026076265A1 (en) | 2024-10-03 | 2026-04-09 | Gilead Sciences, Inc. | Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3354866A (en) * | 1966-04-25 | 1967-11-28 | Frank D Karkoska | Coating apparatus including means to rotate and translate a rod-substrate |
| US3882114A (en) * | 1967-10-26 | 1975-05-06 | Oreal | N-(morpholinomethyl carbamyl) cysteamine and glycine |
| GB1339764A (en) * | 1971-03-29 | 1973-12-05 | Ici Ltd | Pyridine derivatives |
| US3957774A (en) * | 1972-04-17 | 1976-05-18 | L'oreal | N-morpholinomethyl-n-'-substituted ethyl and propylureas |
| US5142056A (en) | 1989-05-23 | 1992-08-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| HU186777B (en) | 1981-07-09 | 1985-09-30 | Magyar Tudomanyos Akademia | Process for producing complex-forming agents of crown-ether base and ionoselective membranelektrodes containing them |
| DE3478684D1 (en) * | 1983-11-02 | 1989-07-20 | Magyar Tudomanyos Akademia | Crown ether derivatives |
| US5552558A (en) | 1989-05-23 | 1996-09-03 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5362912A (en) | 1989-05-23 | 1994-11-08 | Abbott Laboratories | Process for the preparation of a substituted diaminodiol |
| US5354866A (en) | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| EP0428849A3 (en) | 1989-09-28 | 1991-07-31 | Hoechst Aktiengesellschaft | Retroviral protease inhibitors |
| US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
| US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| IE913840A1 (en) | 1990-11-20 | 1992-05-20 | Abbott Lab | Retroviral protease inhibiting compounds |
| JPH06127981A (ja) | 1992-03-03 | 1994-05-10 | Fuainiteii Kk | 複合複層ガラス及びそれを使用した窓 |
| US5556418A (en) * | 1993-07-06 | 1996-09-17 | Pappas; Panagiotis T. | Method and apparatus for pulsed magnetic induction |
| US5968942A (en) * | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
| EP1302468B1 (en) | 1992-12-29 | 2008-12-17 | Abbott Laboratories | Processes and intermediates for manufacturing retroviral protease inhibiting compounds |
| US5567592A (en) | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
| UA49803C2 (uk) * | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Спосіб лікування ретровірусних інфекцій |
| US5567823A (en) | 1995-06-06 | 1996-10-22 | Abbott Laboratories | Process for the preparation of an HIV protease inhibiting compound |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US5763464A (en) | 1995-11-22 | 1998-06-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| WO1999033792A2 (en) * | 1997-12-24 | 1999-07-08 | Vertex Pharmaceuticals Incorporated | Prodrugs os aspartyl protease inhibitors |
| FR2773994B1 (fr) | 1998-01-23 | 2002-10-11 | Univ Nice Sophia Antipolis | Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central |
| FR2779653B1 (fr) * | 1998-06-11 | 2002-12-20 | Inst Nat Sante Rech Med | Utilisation de composes modulateurs du proteasome en therapie |
| ATE332132T1 (de) | 1999-06-04 | 2006-07-15 | Abbott Lab | Verbesserte arzneizubereitungen enthaltend ritonavir |
| EP1222192B8 (en) | 1999-10-06 | 2008-10-01 | Tibotec Pharmaceuticals Ltd. | Hexahydrofuro¬2,3-b furan-3-yl-n- 3-¬(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino -1-benzyl-2-hydroxypropyl carbamate as retroviral protease inhibitor |
| US6252336B1 (en) | 1999-11-08 | 2001-06-26 | Cts Corporation | Combined piezoelectric silent alarm/battery charger |
| AU2001259817A1 (en) * | 2000-05-04 | 2001-11-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health | Methods of and compounds for inhibiting calpains |
| US7193065B2 (en) * | 2001-07-13 | 2007-03-20 | Roche Diagnostics Operations, Inc. | Protease inhibitor conjugates and antibodies useful in immunoassay |
| US6946449B2 (en) | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| US7285566B2 (en) | 2002-01-07 | 2007-10-23 | Erickson John W | Resistance-repellent retroviral protease inhibitors |
| EP1467970B1 (en) | 2002-01-17 | 2007-08-22 | Merck & Co., Inc. | Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors |
| US7205413B2 (en) * | 2002-05-03 | 2007-04-17 | Transform Pharmaceuticals, Inc. | Solvates and polymorphs of ritonavir and methods of making and using the same |
| EP2161258A3 (en) | 2002-11-20 | 2010-04-07 | Japan Tabacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| JP2004184681A (ja) * | 2002-12-03 | 2004-07-02 | Konica Minolta Holdings Inc | 熱現像感光材料 |
| MXPA05007016A (es) | 2003-01-14 | 2005-09-12 | Gilead Sciences Inc | Composiciones y metodos para terapia antiviral de combinacion. |
| TW200505441A (en) | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
| US7737608B2 (en) | 2003-07-30 | 2010-06-15 | The Boeing Company | Enhanced amplitude piezoelectric motor apparatus and method |
| JP2005091988A (ja) * | 2003-09-19 | 2005-04-07 | Konica Minolta Medical & Graphic Inc | 熱現像感光材料及び画像形成方法 |
| CA2543696A1 (en) * | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Combinations for hcv treatment |
| BRPI0401742B8 (pt) | 2004-05-13 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir |
| MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| JP2006003701A (ja) * | 2004-06-18 | 2006-01-05 | Konica Minolta Medical & Graphic Inc | 熱現像感光材料および画像形成方法 |
| CN101023090B (zh) * | 2004-07-06 | 2013-03-27 | 雅培制药有限公司 | Hiv蛋白酶抑制剂的前药 |
| US7786153B2 (en) | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| SG183007A1 (en) | 2006-07-07 | 2012-08-30 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
| WO2008027932A2 (en) | 2006-08-31 | 2008-03-06 | Abbott Laboratories | Cytochrome p450 oxidase inhibitors and uses thereof |
| PL3150586T3 (pl) * | 2007-02-23 | 2020-06-01 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości środków terapeutycznych |
| AR067184A1 (es) | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica |
| WO2009006199A1 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
| EP2170851B1 (en) * | 2007-07-06 | 2013-09-04 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| WO2009086356A2 (en) | 2007-12-27 | 2009-07-09 | Baxter International Inc. | Method and compositions for specifically detecting physiologically acceptable polymer molecules |
| HRP20151357T1 (hr) | 2008-05-02 | 2016-01-29 | Gilead Sciences, Inc. | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa |
| DK2393485T3 (en) | 2009-02-06 | 2015-10-26 | Gilead Sciences Inc | Bilayer COVERING ELVITEGRAVIR, COBICISTAT, emtricitabine and tenofovir |
-
2007
- 2007-07-06 SG SG2012050464A patent/SG183007A1/en unknown
- 2007-07-06 MX MX2009000234A patent/MX2009000234A/es active IP Right Grant
- 2007-07-06 RS RS20150590A patent/RS54237B2/sr unknown
- 2007-07-06 JP JP2009518393A patent/JP4881433B2/ja active Active
- 2007-07-06 WO PCT/US2007/015604 patent/WO2008010921A2/en not_active Ceased
- 2007-07-06 PT PT121675946T patent/PT2487165T/pt unknown
- 2007-07-06 ES ES16180602T patent/ES2796275T3/es active Active
- 2007-07-06 HU HUE07836007A patent/HUE025565T4/en unknown
- 2007-07-06 AU AU2007275860A patent/AU2007275860C1/en active Active
- 2007-07-06 CN CN201310141408.6A patent/CN103275033B/zh active Active
- 2007-07-06 CA CA002653374A patent/CA2653374A1/en not_active Abandoned
- 2007-07-06 PT PT78360070T patent/PT2049506E/pt unknown
- 2007-07-06 ES ES07836007T patent/ES2546378T5/es active Active
- 2007-07-06 US US12/306,198 patent/US8067449B2/en active Active
- 2007-07-06 KR KR1020137033735A patent/KR20140004808A/ko not_active Ceased
- 2007-07-06 EP EP07836007.0A patent/EP2049506B2/en active Active
- 2007-07-06 EP EP20167933.9A patent/EP3696171B1/en active Active
- 2007-07-06 EP EP16180602.1A patent/EP3112355B1/en active Active
- 2007-07-06 PL PL07836007.0T patent/PL2049506T5/pl unknown
- 2007-07-06 ME MEP-2015-590A patent/ME02258B/me unknown
- 2007-07-06 EA EA200900155A patent/EA020489B1/ru active Protection Beyond IP Right Term
- 2007-07-06 ES ES20167933T patent/ES3026665T3/es active Active
- 2007-07-06 KR KR1020097002544A patent/KR101477822B1/ko active Active
- 2007-07-06 CN CN2007800256073A patent/CN101490023B/zh active Active
- 2007-07-06 EP EP25158282.1A patent/EP4566670A3/en active Pending
- 2007-07-06 EA EA201270738A patent/EA025845B1/ru active Protection Beyond IP Right Term
- 2007-07-06 SI SI200731667T patent/SI2049506T2/sl unknown
- 2007-07-06 EP EP12167594.6A patent/EP2487165B1/en active Active
- 2007-07-06 NZ NZ573060A patent/NZ573060A/en unknown
- 2007-07-06 TW TW102126891A patent/TWI496778B/zh active
- 2007-07-06 ES ES12167594.6T patent/ES2611308T3/es active Active
- 2007-07-06 KR KR1020157008020A patent/KR101636221B1/ko active Active
- 2007-07-06 PL PL20167933.9T patent/PL3696171T3/pl unknown
- 2007-07-06 TW TW096124727A patent/TWI411613B/zh active
- 2007-07-06 HR HRP20150744TT patent/HRP20150744T4/hr unknown
- 2007-07-06 BR BRPI0714055A patent/BRPI0714055B8/pt active IP Right Grant
- 2007-07-06 US US11/825,605 patent/US7939553B2/en active Active
- 2007-07-06 DK DK07836007.0T patent/DK2049506T4/da active
- 2007-07-06 AP AP2008004720A patent/AP2985A/xx active
- 2007-07-06 HR HRP20090077AA patent/HRP20090077B1/hr not_active IP Right Cessation
- 2007-07-06 AR ARP070103029A patent/AR061838A1/es active IP Right Grant
-
2008
- 2008-11-25 IL IL195488A patent/IL195488A/en active IP Right Grant
-
2009
- 2009-02-06 NO NO20090593A patent/NO343776B1/no active Protection Beyond IP Right Term
-
2011
- 2011-05-09 US US13/103,970 patent/US8383655B2/en active Active
- 2011-10-31 JP JP2011239688A patent/JP2012051933A/ja not_active Withdrawn
-
2013
- 2013-01-10 US US13/738,764 patent/US20130123311A1/en not_active Abandoned
- 2013-12-20 US US14/137,555 patent/US20140105859A1/en not_active Abandoned
-
2014
- 2014-04-29 IL IL232320A patent/IL232320A0/en unknown
- 2014-05-02 US US14/268,891 patent/US20150011775A1/en not_active Abandoned
-
2015
- 2015-01-20 US US14/601,132 patent/US9139541B2/en active Active
- 2015-08-17 US US14/828,406 patent/US20160067360A1/en not_active Abandoned
- 2015-09-14 CY CY20151100800T patent/CY1116688T1/el unknown
- 2015-11-06 FI FIC20150052C patent/FIC20150052I1/fi unknown
- 2015-11-06 LU LU92864C patent/LU92864I2/xx unknown
- 2015-11-06 FI FIEP07836007.0T patent/FI2049506T4/fi active
- 2015-11-11 LT LTPA2015040C patent/LTC2049506I2/lt unknown
- 2015-11-26 CY CY2015046C patent/CY2015046I1/el unknown
- 2015-12-02 FR FR15C0078C patent/FR15C0078I2/fr active Active
- 2015-12-08 NL NL300780C patent/NL300780I2/nl unknown
-
2016
- 2016-03-17 US US15/073,367 patent/US20160303088A1/en not_active Abandoned
- 2016-11-01 US US15/340,466 patent/US20170143680A1/en not_active Abandoned
-
2017
- 2017-12-05 US US15/831,703 patent/US20180221348A1/en not_active Abandoned
-
2019
- 2019-04-23 NO NO20190528A patent/NO345343B1/no unknown
- 2019-07-04 NO NO2019027C patent/NO2019027I1/no unknown
- 2019-07-19 NO NO2019031C patent/NO2019031I1/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4881433B2 (ja) | 治療薬の薬物動態の調整 | |
| JP6192776B2 (ja) | 治療薬の薬物動態特性の調節 | |
| JP2009542696A5 (https=) | ||
| JP5629585B2 (ja) | シトクロムｐ４５０のインヒビター | |
| JP5393665B2 (ja) | 治療剤の薬物動態特性の調整剤 | |
| JP2010519314A5 (https=) | ||
| NO20200578A1 (no) | Modulatorer av farmakokinetikkegenskaper til terapeutika | |
| HK1143144B (en) | Modulators of pharmacokinetic properties of therapeutics | |
| NO20230434A1 (no) | Modulatorer av farmakokinetikkegenskaper til terapeutika |